The abnormal amplification and phosphorylation of p62/SQSTM1 has been linked to tumor growth and cisplatin resistance in patient-derived high-grade serous ovarian cancer cells [532]. This evidence concerns the gene SQSTM1 and ovarian serous adenocarcinoma.